Published in Med J Aust on January 15, 2007
Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis (2007) 2.56
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis (2010) 1.11
Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies. Med J Aust (2007) 1.09
Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Negl Trop Dis (2011) 1.09
The incubation period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS Negl Trop Dis (2013) 1.01
Mycobacterium ulcerans infection in Brazil. Med J Aust (2007) 0.85
Buruli ulcer disease in travelers and differentiation of Mycobacterium ulcerans strains from northern Australia. J Clin Microbiol (2012) 0.78
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services. Med J Aust (2013) 4.93
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis (2011) 3.98
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res (2007) 3.45
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust (2007) 2.97
Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol (2007) 2.75
2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis (2010) 2.60
Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis (2007) 2.56
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 2.43
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust (2009) 2.16
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol (2006) 2.10
Methicillin-resistant Staphylococcus aureus in hospitals: time for a culture change. Med J Aust (2007) 2.06
Conundrums in community-acquired pneumonia. Med J Aust (2006) 2.04
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.89
A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis (2010) 1.80
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog (2010) 1.74
Outbreak investigation using high-throughput genome sequencing within a diagnostic microbiology laboratory. J Clin Microbiol (2013) 1.71
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis (2009) 1.67
Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat Genet (2013) 1.67
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust (2007) 1.56
Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol (2008) 1.46
Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance. J Bacteriol (2010) 1.43
Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother (2006) 1.43
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 1.38
Genomic insights to control the emergence of vancomycin-resistant enterococci. MBio (2013) 1.37
Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis (2010) 1.37
A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203. J Infect Dis (2010) 1.27
Comparative analysis of the first complete Enterococcus faecium genome. J Bacteriol (2012) 1.27
Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis (2003) 1.23
Evaluation of VNTR typing for the identification of Mycobacterium ulcerans in environmental samples from Victoria, Australia. FEMS Microbiol Lett (2008) 1.21
The dominant Australian community-acquired methicillin-resistant Staphylococcus aureus clone ST93-IV [2B] is highly virulent and genetically distinct. PLoS One (2011) 1.16
Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans. J Bacteriol (2003) 1.15
Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis (2009) 1.15
Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust (2002) 1.14
Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother (2003) 1.13
Epidemiology and management of Buruli ulcer. Expert Rev Anti Infect Ther (2014) 1.13
Outcomes from the first 2 years of the Australian National Hand Hygiene Initiative. Med J Aust (2011) 1.13
Severe complications of a "Brazilian" bikini wax. Clin Infect Dis (2007) 1.13
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrob Agents Chemother (2005) 1.11
All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis (2010) 1.11
Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust (2007) 1.09
Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Negl Trop Dis (2011) 1.09
Complete genome sequence of the frog pathogen Mycobacterium ulcerans ecovar Liflandii. J Bacteriol (2012) 1.08
Spontaneous clearance of Mycobacterium ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis (2011) 1.08
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Australia's influenza containment plan and the swine flu epidemic in Victoria. Med J Aust (2009) 1.08
Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol (2012) 1.07
Extensively resistant tuberculosis in the lands Down Under. Med J Aust (2011) 1.07
The genome, evolution and diversity of Mycobacterium ulcerans. Infect Genet Evol (2012) 1.06
Climate and landscape factors associated with Buruli ulcer incidence in Victoria, Australia. PLoS One (2012) 1.06
Pathogenicity in the tubercle bacillus: molecular and evolutionary determinants. Bioessays (2009) 1.06
Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactones. BMC Genomics (2008) 1.04
Direct detection of Mycobacterium ulcerans in clinical specimens and environmental samples. Methods Mol Biol (2013) 1.04
Evidence of primary transmission of multidrug-resistant tuberculosis in the Western Province of Papua New Guinea. Med J Aust (2008) 1.03
Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care (2011) 1.03
The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus. J Infect Dis (2012) 1.02